🇺🇸 FDA
Patent

US 8057807

Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction

granted A61KA61K31/16A61K31/353

Quick answer

US patent 8057807 (Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction) held by The Regents of the University of Colorado, a Body Corporate expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/16, A61K31/353, A61K38/4893, A61P